-
Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use J. Psychopharmacol. (IF 4.1) Pub Date : 2024-03-14 Ivan Papic, Petra Bistrovic, Ivan Krecak, Maja Ortner Hadziabdic, Marko Lucijanic
Background:Due to non-consistent reports in the literature, there are uncertainties about the potential benefits and harms of selective serotonin reuptake inhibitors (SSRIs) in patients with Coronavirus disease 2019 (COVID-19).Aim:To investigate associations of SSRIs with clinical characteristics and unwanted outcomes among real-life severe and critical COVID-19 patients and their relationship with
-
Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression J. Psychopharmacol. (IF 4.1) Pub Date : 2024-03-13 Nelson B Rodrigues, David Chen-Li, Joshua D Di Vincenzo, Ashwin Juneja, Benjamin D Pinder, Roger S McIntyre, Joshua D Rosenblat
Background:Converging lines of evidence indicate that ketamine is a rapid antidepressant for individuals with treatment-resistant depression. Hitherto, no reliable a priori predictors of ketamine response have been reported. Pharmacogenetic biomarkers have yielded mixed results regarding potential candidate genes associated with ketamine’s biochemistry as reliable predictors of response.Aims:No studies
-
Psychiatric risks for worsened mental health after psychedelic use J. Psychopharmacol. (IF 4.1) Pub Date : 2024-03-04 Alessia Marrocu, Hannes Kettner, Brandon Weiss, Richard J Zeifman, David Erritzoe, Robin L Carhart-Harris
Background:Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited by biases
-
The neural oscillations serving task switching are altered in cannabis users J. Psychopharmacol. (IF 4.1) Pub Date : 2024-02-29 Kellen M McDonald, Mikki Schantell, Lucy K Horne, Jason A John, Maggie P Rempe, Ryan Glesinger, Hannah J Okelberry, Anna T Coutant, Seth D Springer, Amirsalar Mansouri, Christine M Embury, Yasra Arif, Tony W Wilson
Background:Regular cannabis is known to impact higher-order cognitive processes such as attention, but far less is known regarding cognitive flexibility, a component of executive function. Moreover, whether such changes are related to aberrations in the neural oscillatory dynamics serving flexibility remains poorly understood.Aims:Quantify the neural oscillatory dynamics serving cognitive flexibility
-
In Memoriam: Professor Brian Leonard (1936–2023) J. Psychopharmacol. (IF 4.1) Pub Date : 2024-02-27 John P Kelly, John F Cryan, David P Finn
-
The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis J. Psychopharmacol. (IF 4.1) Pub Date : 2024-02-22 Arman Shafiee, Razman Arabzadeh Bahri, Mohammad Ali Rafiei, Fatemeh Esmaeilpur Abianeh, Parsa Razmara, Kyana Jafarabady, Mohammad Javad Amini
Background:Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within the brain.Aims:Integrated review and analysis of different studies in this field.Methods:A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023
-
What is the impact of antidepressant side effects on medication adherence among adult patients diagnosed with depressive disorder: A systematic review J. Psychopharmacol. (IF 4.1) Pub Date : 2024-02-12 Eleni Niarchou, LH Roberts, Bernard D. Naughton
Background:Medication adherence is a prerequisite to achieving beneficial treatment outcomes. In major depressive disorder, many patients fail to complete medication regimens, raising concern for poor treatment outcomes. It is usual to experience adverse drug reactions (ADRs) while taking antidepressants, and relative discomfort is reported by patients.Aims:The present review focuses on the presence
-
Mifepristone decreases nicotine intake in dependent and non-dependent adult rats J. Psychopharmacol. (IF 4.1) Pub Date : 2024-02-09 Ranjithkumar Chellian, Azin Behnood-Rod, Adriaan W Bruijnzeel
Background:Addiction to tobacco and nicotine products has adverse health effects and afflicts more than a billion people worldwide. Therefore, there is an urgent need for new treatments to reduce tobacco and nicotine use. Glucocorticoid receptor blockade shows promise as a novel treatment for drug abuse and stress-related disorders.Aim:These studies aim to investigate whether glucocorticoid receptor
-
A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance J. Psychopharmacol. (IF 4.1) Pub Date : 2024-02-09 Brooke Manning, Thomas R Arkell, Amie C Hayley, Luke A Downey
Background:Despite increasing medical cannabis use, research has yet to establish whether and to what extent products containing delta-9-tetrahydrocannabinol (THC) impact driving performance among patients. Stable doses of prescribed cannabinoid products during long-term treatment may alleviate clinical symptoms affecting cognitive and psychomotor performance.Aim:To examine the effects of open-label
-
Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats J. Psychopharmacol. (IF 4.1) Pub Date : 2024-02-08 Giorgio Bergamini, Sean Durkin, Michel Alexander Steiner
In rodents, orexin neuropeptides regulate motivation and reward-seeking via orexin 1 receptor (OX1R) signaling in the mesolimbic dopaminergic system. This role is clearly established for rewards inherent to drugs of abuse but less so for natural rewards. Reported effects of the selective OX1R antagonist (SO1RA) SB-334867 on motivation for palatable food are ambiguous. In our experimental conditions
-
Role of α1-GABAA receptors in the serotonergic dorsal raphe nucleus in models of opioid reward, anxiety, and depression J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-31 Chen Li, Bryan D McElroy, Jared Phillips, Nicholas S McCloskey, Xiangdang Shi, Ellen M Unterwald, Lynn G Kirby
Background:The serotonin (5-hydroxytryptamine (5-HT))-mediated system plays an important role in stress-related psychiatric disorders and substance abuse. Our previous studies showed that stress and drug exposure can modulate the dorsal raphe nucleus (DRN)-5-HT system via γ-aminobutyric acid (GABA)A receptors. Moreover, GABAA receptor-mediated inhibition of serotonergic DRN neurons is required for
-
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-31 Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott
Background:The N-methyl-D-aspartate antagonist ketamine has rapid onset antidepressant activity in treatment-resistant depression (TRD).Aims:To evaluate mood rating, safety and tolerability data from patients with TRD treated with ketamine and the psychoactive control fentanyl, as part of a larger study to explore EEG biomarkers associated with mood response.Methods:We evaluated the efficacy and safety
-
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-28 Jessica Barbut Siva, Tommaso Barba, Hannes Kettner, Joanna Kuc, David J Nutt, Robin Carhart-Harris, David Erritzoe
Background:There is growing evidence for the therapeutic effects of psychedelics. However, it is still uncertain how these drugs interact with serotonergic antidepressants (serotonin reuptake inhibitors (SRIs)).Objective:This study explores the interaction between psychedelics and SRIs in terms of therapeutic effects. The objective is to compare acute psychedelic effects and subsequent changes in well-being
-
Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-27 Po-Yu Chen, Chih-Chiang Chiu, Chin-Kuo Chang, Mong-Liang Lu, Cho-Yin Huang, Chun-Hsin Chen, Ming-Chyi Huang
Background:Clozapine is the primary antipsychotic (APD) for treatment-resistant schizophrenia (TRS). However, only 40% of patients with TRS respond to clozapine, constituting a subgroup of clozapine-resistant patients. Recently, the neuropeptide orexin-A was shown to be involved in the pathophysiology of schizophrenia. This study evaluated the association of orexin-A levels with the clozapine response
-
MDMA enhances positive affective responses to social feedback J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-27 Anya K Bershad, David T Hsu, Harriet de Wit
Background:The prosocial compound ± 3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has shown promise as an adjunct to psychotherapy in the treatment of post-traumatic stress disorder. MDMA increases positive responses to social images, and it has been suggested that the ability of MDMA to positively bias social perception may underlie its therapeutic efficacy as a psychotherapy
-
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-27 April C May, Kaiping Burrows, Rayus Kuplicki, Martin P Paulus, Jennifer L Stewart
Background:Dysregulated ventral striatum function has been proposed as one important process occurring in individuals with substance use disorder. This study investigates the role of altered reward and loss processing, which is an important component of impaired decision-making, impulsivity, and vulnerability to relapse in individuals with amphetamine use disorder (AMP).Aims:To determine whether AMP
-
Older adults in psychedelic-assisted therapy trials: A systematic review J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-19 Lisa Bouchet, Zachary Sager, Antoine Yrondi, Kabir B Nigam, Brian T Anderson, Stephen Ross, Petros D Petridis, Yvan Beaussant
Background:Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential
-
The impact of cannabidiol placebo on responses to an acute stressor: A replication and proof of concept study J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-12 Radostina M Zhekova, Robin N Perry, Toni C Spinella, Kayley Dockrill, Sherry H Stewart, Sean P Barrett
Background:Our group has previously reported that cannabidiol (CBD) expectancy alone blunts markers of stress, particularly during anticipation, but it is not clear the extent to which such findings were specific to the methods utilized.Aims:To examine CBD-related placebo effects on stress reactivity and anticipation and to validate a protocol to be used in a neuroimaging study.Methods:Forty-eight
-
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins J. Psychopharmacol. (IF 4.1) Pub Date : 2024-01-12 Antonin Rouaud, Abigail E. Calder, Gregor Hasler
Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly involves ingesting sub-threshold doses of lysergic acid diethylamide (LSD), psilocybin, or other psychedelic drugs 2–4 times a week for at least several weeks, but potentially months or years. Concerningly, both LSD and psilocybin share structural similarities
-
Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-27 Brian J Gully,Erica Eaton,Christy Capone,Carolina L Haass-Koffler
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity leads to a vicious cycle where PTSD symptoms beget heavy drinking and vice versa. There are no FDA-approved medications to treat PTSD-AUD; therefore, individuals suffering from this comorbidity are treated with medication approved to treat the disorders separately
-
The 5-HT7 receptor system as a treatment target for mood and anxiety disorders: A systematic review. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-23 Natalie Gottlieb,Tse-Yi Li,Allan H Young,Paul Ra Stokes
BACKGROUND Preclinical animal and preliminary human studies indicate that 5-HT7 antagonists have the potential as a new treatment approach for mood and anxiety disorders. In this systematic review, we aimed to review the relationship between the 5-HT7 receptor system and mood and anxiety disorders, and to explore the pharmacology and therapeutic potential of medications that target the 5-HT7 receptor
-
Value-based decision-making predicts alcohol use and related problems in young men. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-23 Johannes Petzold,Angela Hentschel,Hao Chen,Sören Kuitunen-Paul,Edythe D London,Andreas Heinz,Michael N Smolka
BACKGROUND Alcohol consumption is a leading cause of morbidity and mortality worldwide, disproportionately affecting young men. Heavy episodic drinking is particularly prevalent among men, with this behavior peaking between the ages of 20 and 24. AIMS We sought to identify dimensions of decision-making in men that would predict the development of hazardous alcohol use through emerging adulthood. METHODS
-
Drug-drug interactions involving classic psychedelics: A systematic review. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-20 Andreas Halman,Geraldine Kong,Jerome Sarris,Daniel Perkins
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes when using these substances in combination with other
-
Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-20 Michel A Steiner,Michael Toeroek-Schafroth,Lisa Dacome,Michela Tessari
For abuse potential assessment, U.S. Food and Drug Administration (FDA) requests that new, brain-penetrating drugs are ideally compared with approved drugs that share the mechanism of action and are judged to have abuse liability by the Drug Enforcement Agency. For development of the dual orexin receptor antagonist (DORA) daridorexant, the FDA recommended conducting a rat drug discrimination paradigm
-
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-16 Oliver Rumle Hovmand,Emil Deleuran Poulsen,Sidse Arnfred
BACKGROUND The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of consciousness, characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning. It is important to have reliable instruments for quantifying these altered states in trials, due to a plausible link
-
The psychedelic effects of cannabis: A review of the literature. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-10 David Wolinsky,Frederick Streeter Barrett,Ryan Vandrey
Cannabis and classic psychedelics are controlled substances with emerging evidence of efficacy in the treatment of a variety of psychiatric illnesses. Cannabis has largely not been regarded as having psychedelic effects in contemporary literature, despite many examples of historical use along with classic psychedelics to attain altered states of consciousness. Research into the "psychedelic" effects
-
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-09 Michael Kaczmarczyk,Madeleine Batke,Katja Wingenfeld,Christian Eric Deuter,Christian Otte
BACKGROUND The mood stabilizer lithium has a narrow therapeutic index with a relevant risk of intoxication. We used real-world hospital data to identify causes, treatment courses, and outcomes of high lithium levels and intoxications. METHODS Retrospective chart review of patients with a lithium concentration of ⩾1.1 mmol/L, who were treated at Charité University Medical Center Berlin. RESULTS We identified
-
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α2-adrenoceptor sensitivity. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-09 Mostafa El Mansari,Rami Hamoudeh,Stephen Daniels,Pierre Blier
BACKGROUND Wistar Kyoto (WKY) rats manifest abnormalities in the function of monoamine receptors and transporters, as well as levels of these neurotransmitters in the brain. The present study assessed alterations in the firing activity of serotonin (5-hydroxytryptamine [5-HT]), norepinephrine (NE), and dopamine (DA) neurons, as well as the activity of 5-HT and NE receptors and transporters in the hippocampus
-
Kynurenine pathway and suicidal ideation in treatment-resistant depression. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-08 Abdulla A-B Badawy
-
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-08 Genís Ona,Ingrid Reverte,Giordano N Rossi,Rafael G Dos Santos,Jaime Ec Hallak,Maria Teresa Colomina,José Carlos Bouso
BACKGROUND There is a growing interest in studying ibogaine (IBO) as a potential treatment for substance use disorders (SUDs). However, its clinical use has been hindered for mainly two reasons: First, the lack of randomized, controlled studies informing about its safety and efficacy. And second, IBO's mechanisms of action remain obscure. It has been challenging to elucidate a predominant mechanism
-
The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-11-08 Laura Korb,Samuel Tromans,Bhathika Perera,Nagina Khan,Lisa Burrows,Richard Laugharne,Angela Hassiotis,Victoria Allgar,Daryl Efron,Ian Maidment,Rohit Shankar
BACKGROUND Around 2% of the population have intellectual disabilities. Over one-third people with intellectual disabilities (PwID) present with 'challenging behaviour', which nosologically and diagnostically is an abstract concept. Challenging behaviour is influenced by a range of bio-psycho-social factors in a population, which is unable to suitably comprehend and/or communicate concerns. This predisposes
-
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-10-31 Kurt Stocker,Matthias Hartmann,Laura Ley,Anna M Becker,Friederike Holze,Matthias E Liechti
BACKGROUND Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Experience Questionnaire (MEQ)). The psychometric potential of the non-MEQ items of the PES remains largely unexplored. AIMS We investigated whether the PES also yields subscales besides the MEQ30 subscales. METHODS Data from 239 PES measurements (140 healthy
-
Psychological and physiological effects of extended DMT. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-10-28 Lisa X Luan,Emma Eckernäs,Michael Ashton,Fernando E Rosas,Malin V Uthaug,Alexander Bartha,Samantha Jagger,Kiara Gascon-Perai,Lauren Gomes,David J Nutt,David Erritzøe,Robin L Carhart-Harris,Christopher Timmermann
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make DMT a powerful tool for the neuroscientific study of consciousness and preliminary results show its potential role in treating mental health conditions. In a within-subjects, placebo-controlled
-
Clinical quandaries in psychotic disorders: the road is long, with many a winding turn. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-10-16 Sameer Jauhar,Robert A McCutcheon
-
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2). J. Psychopharmacol. (IF 4.1) Pub Date : 2023-10-16 Matthew Kt McAdam,Ross J Baldessarini,Andrea L Murphy,David M Gardner
BACKGROUND Expert consensus-based clinically equivalent dose estimates and dosing recommendations can provide valuable support for the use of drugs for psychosis in clinical practice and research. AIMS This second International Consensus Study of Antipsychotic Dosing provides dosing equivalencies and recommendations for newer drugs for psychosis and previously reported drugs with low consensus. METHODS
-
Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-10-16 Natalia Malikowska-Racia,Maciej Koniewski,Joanna Golebiowska,Piotr Popik
BACKGROUND In clinical studies, psychedelics including psilocybin and D-lysergic acid diethylamide (LSD) demonstrate rapid and persistent antidepressant effects. Since the effective treatment with psychedelics is usually provided with psychotherapy, it is debatable whether their prolonged efficacy can be observed in infrahuman species. Preclinical reports on psychedelics' effects most often address
-
Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-10-09 Yuya Mizuno,Abhishekh Hulegar Ashok,Bhagyashree Bhaskar Bhat,Sameer Jauhar,Oliver D Howes
BACKGROUND Major depressive disorder (MDD) is a leading cause of global disability. Several lines of evidence implicate the dopamine system in its pathophysiology. However, the magnitude and consistency of the findings are unknown. We address this by systematically reviewing in vivo imaging evidence for dopamine measures in MDD and meta-analysing these where there are sufficient studies. METHODS Studies
-
Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose-response model-based network meta-analysis. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-09-23 Itsuki Terao,Asato Yokoi,Hirotaka Fukushima
BACKGROUND Quetiapine has varied dose ranges and immediate-(QTP-IR) and extended-release (QTP-ER) formulations. AIMS We hypothesized that QTP-IR is inferior to QTP-ER at any dose in efficacy for the acute treatment in schizophrenia and tested using a dose-response model-based network meta-analysis (NMA). METHODS We searched PubMed, the Cochrane Library, CINHAL, and ClinicalTrials.gov for randomized
-
Exploring the efficacy and safety of a novel standardized ashwagandha (Withania somnifera) root extract (Witholytin®) in adults experiencing high stress and fatigue in a randomized, double-blind, placebo-controlled trial. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-09-23 Stephen J Smith,Adrian L Lopresti,Timothy J Fairchild
BACKGROUND Stress is a state of homeostasis in the body being challenged, resulting in a systemic response. It has become more prevalent in recent years and affects mental and physical health. AIMS Evaluate the effects of ashwagandha on stress, fatigue, and sex hormones in overweight or mildly obese men and women with self-reported stress and fatigue. METHODS Two-arm, parallel-group, 12-week, randomized
-
Acute administration of alprazolam, alcohol and their combination on cognitive performance and mood: A randomised, double-blind, placebo-controlled study. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-09-19 Blair Aitken,Amie C Hayley,Talitha C Ford,Lauren Geier,Brook A Shiferaw,Luke A Downey
BACKGROUND Recreational co-consumption of benzodiazepines and alcohol is a common practise; yet, the cognitive effects of this combination remain poorly understood. This study aimed to investigate the acute cognitive effects of combining a 1 mg dose of alprazolam with a moderate dose of alcohol (target 0.04% blood alcohol concentration (BAC)) in a non-clinical population. METHODS In this randomised
-
Predicting clozapine dose required to achieve a therapeutic plasma concentration - A comparison of a population algorithm and three algorithms based on gene variant models. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-09-12 David Taylor,Caroline Cahill,Paul Wallang,Louise Millard,Luis Ramudo Cela,Kieran C Breen
BACKGROUND Clozapine is the most effective antipsychotic but requires careful titration to therapeutic blood levels. Methods to predict therapeutic doses are based on population data. AIMS We aimed to construct a model based on genetic variants which accurately predicted plasma levels for clozapine. METHOD We measured clozapine plasma levels in patients on a stable dose of clozapine who were known
-
Psilocybin history, action and reaction: A narrative clinical review. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-31 Pravesh Sharma,Quang Anh Nguyen,Sadie J Matthews,Erin Carpenter,Douglas B Mathews,Christi A Patten,Christopher J Hammond
Hallucinogenic mushrooms have been used in religious and cultural ceremonies for centuries. Of late, psilocybin, the psychoactive compound in hallucinogenic mushrooms, has received increased public interest as a novel drug for treating mood and substance use disorders (SUDs). In addition, in recent years, some states in the United States have legalized psilocybin for medical and recreational use. Given
-
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-18 Daniela Braida,Luisa Ponzoni,Ilaria Dellarole,Stefano Morara,Mariaelvina Sala
BACKGROUND Nicotine cessation leads to anxiety and depression. AIMS The suitability of the zebrafish model of anhedonia using reserpine and fluoxetine was evaluated. Fluoxetine was also used to reduce nicotine withdrawal-induced anhedonic state. METHODS Zebrafish were exposed to reserpine (40 mg/l) and then to fluoxetine (0.1 mg/l) for 1 week. Anhedonia was evaluated in the Novel Tank Diving and Compartment
-
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-17 Marco Paolini,Yasmin Harrington,Federica Colombo,Valentina Bettonagli,Sara Poletti,Matteo Carminati,Cristina Colombo,Francesco Benedetti,Raffaella Zanardi
BACKGROUND For many patients with major depressive disorder (MDD) adequate treatment remains elusive. Neuroimaging techniques received attention for their potential use in guiding and predicting response, but were rarely investigated in real-world psychiatric settings. AIMS To identify structural and functional Magnetic Resonance Imaging (MRI) biomarkers associated with antidepressant response in a
-
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-12 Michael Tagen,Daniel Mantuani,Liron van Heerden,Alex Holstein,Linda E Klumpers,Richard Knowles
Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT2B receptor. However, this risk has not yet been comprehensively assessed. This analysis
-
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-04 Reza Rafizadeh,Laura Frankow,Hajer Mahmood,Sukhpreet Poonia,Nickie Mathew,Marlon Danilewitz,Chad A Bousman,William G Honer,Christian G Schütz
BACKGROUND Preliminary evidence suggest clozapine is associated with more favorable impact on concurrent substance use disorder related outcomes in patients with concurrent schizophrenia spectrum disorders (SSD). At the same time, there is a dearth of evidence with regards to clozapine outcomes in the context of concurrent methamphetamine or amphetamine use disorder (MAUD). AIMS To examine whether
-
QTc prolongation in patients with schizophrenia taking antipsychotics: Prevalence and risk factors. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-03 Wei Du,Meng-Wei Ge,Fei-Hong Hu,Yi-Jie Jia,Dan-Yan Zhao,Yu-Jie Cheng,Hong-Lin Chen
BACKGROUND QTc prolongation is one of the possible complications in patients with schizophrenia taking antipsychotics, which leads to malignant cardiac arrhythmia. No meta-analysis has been reported assessing the prevalence and correlated risk factors for QTc prolongation. METHODS This meta-analysis aimed to assess the evidence for the prevalence of QTc prolongation and correlated risk factors in patients
-
Opioid receptor antagonism and neural response to monetary rewards: Pilot studies in light and heavy alcohol users. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-02 Joshua L Gowin,Matthew E Sloan,Katelyn T Kirk-Provencher,Sophie L Rosenblatt,Anne E Penner,Bethany L Stangl,Nia D Byrd,Julia E Swan,Vijay A Ramchandani
Alcohol use disorder (AUD) is a prevalent condition associated with high degree of comorbidity and mortality. Among the few approved pharmacotherapies for AUD, two involve opioid receptor antagonism. Naltrexone and nalmefene are thought to act via opioid receptor blockage to reduce neural response to alcohol and drug-associated cues and consumption, but there have been limited efforts to characterize
-
Ketamine: A new chapter for clinical psychopharmacology? J. Psychopharmacol. (IF 4.1) Pub Date : 2023-08-01 Allan H Young
-
Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP). J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-31 Sarah J Bailey,Tobias Bast,Lauren Chaby,Bruce J Kinon,Michael K Harte,Sally Mead,Rachel D Moloney,Ian Ragan,S Clare Stanford,Mark D Tricklebank,Mark Zervas,Laura A Ajram
Animal models are important in preclinical psychopharmacology to study mechanisms and potential treatments for psychiatric disorders. A working group of 14 volunteers, comprising an international team of researchers from academia and industry, convened in 2021 to discuss how to improve the translational relevance and interpretation of findings from animal models that are used in preclinical psychopharmacology
-
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-29 Lucinda J Speers,Daena J Sissons,Lana Cleland,David K Bilkey
BACKGROUND Hippocampal phase precession, which depends on the precise spike timing of place cells relative to local theta oscillations, has been proposed to underlie sequential memory. N-methyl-D-asparate (NMDA) receptor antagonists such as ketamine disrupt memory and also reproduce several schizophrenia-like symptoms, including spatial memory impairments and disorganized cognition. It is possible
-
Postpartum psychosis: A proposed treatment algorithm. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-29 Chaitra Jairaj,Gertrude Seneviratne,Veerle Bergink,Iris E Sommer,Paola Dazzan
BACKGROUND Postpartum psychosis (PPP) is a psychiatric emergency that generally warrants acute inpatient care. PPP is marked by the sudden onset of affective and psychotic symptoms with a rapid deterioration in mental state. Evidence suggests that PPP is a discrete disorder on the bipolar disorder spectrum with a distinct treatment profile and prognosis. METHODS We conducted a PubMed database search
-
Association of cannabis use with neurocognition in adolescents with bipolar disorder. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-27 Alysha A Sultan,Megan Mio,Mikaela K Dimick,Yi Zou,Sudhir Karthikeyan,Nathan Kolla,Krista Lanctot,Martin Zack,Benjamin I Goldstein
BACKGROUND Bipolar disorder (BD) and cannabis use are each associated with neurocognitive deficits in adolescents. However, little is known regarding the association of neurocognition with cannabis use among adolescents with BD. Therefore, we examined this topic in a sample of adolescents with BD and healthy control (HC) adolescents. METHODS Participants included 121 adolescents (n = 32 with BD and
-
Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-25 Matthew Burrows,Vasileia Kotoula,Ottavia Dipasquale,Argyris Stringaris,Mitul A Mehta
BACKGROUND Resting state connectivity studies link ketamine's antidepressant effects with normalisation of the brain connectivity changes that are observed in depression. These changes, however, usually co-occur with improvement in depressive symptoms, making it difficult to attribute these changes to ketamine's effects per se. AIMS Our aim is to examine the effects of ketamine in brain connectivity
-
Pentoxifylline as adjunctive therapy in cognitive deficits and symptoms of schizophrenia: A randomized double-blind placebo-controlled clinical trial. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-19 Farideh Sinichi,Farhad Farid Hosseini,Mohammadreza Fayyazi-Bordbar,Mohaddeseh Sinichi,Jamshid Jamali,Amirhooshang Mohammadpour
BACKGROUND Due to the inflammatory factors in the pathophysiology of schizophrenia, Pentoxifylline, as anti-inflammatory medication, seems to improve the symptoms of schizophrenia. This study aims to evaluate the efficacy of Pentoxifylline as an adjunctive therapy on cognitive deficits and symptoms of schizophrenia. METHODS This randomized double-blind placebo-controlled clinical trial was conducted
-
Modafinil: A closer look at its theoretical toxicological potential. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-12 Gabriel Christian de Farias Morais,Edilson Dantas da Silva Junior,Claudio Bruno Silva de Oliveira,João Firmino Rodrigues-Neto,Umberto Laino Fulco,Jonas Ivan Nobre Oliveira
-
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-07 Allan H Young
-
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-04 Oliver Rumle Hovmand,Emil Deleuran Poulsen,Sidse Arnfred,Ole Jakob Storebø
BACKGROUND The classical psychedelics, psilocybin, peyote, ayahuasca/N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promising new treatments for psychiatric illnesses, such as depression, anxiety, addiction, and obsessive-compulsive disorders. However, their profound and characteristic subjective effects raise concern for distinctive biases in randomized clinical trials. METHODS
-
Oral sodium oxybate does not alter plasma kisspeptin levels in healthy male volunteers. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-04 Francesco Bavato,Laura K Schnider,Dario A Dornbierer,Erich Seifritz
Gamma-hydroxybutyrate (GHB, clinically administrated as sodium oxybate) is a GABA-B/GHB receptor agonist inducing prosexual effects and progesterone secretion in humans. As the neuropeptide kisspeptin has well-established roles in regulating sexual behavior and as it was also associated with GABA-B receptor and progesterone function, we investigated the effect of two GHB doses (20 and 35 mg/kg p.o
-
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. J. Psychopharmacol. (IF 4.1) Pub Date : 2023-07-03 Fumiaki Yamasaki,Nobuhisa Kanahara,Yusuke Nakata,Shinji Koyoshi,Yuta Yanagisawa,Takeru Saito,Takahiro Oiwa,Masanobu Kogure,Tsuyoshi Sasaki,Taisuke Yoshida,Hiroshi Kimura,Masaomi Iyo
BACKGROUND Several studies have reported that a switch to the dopamine partial agonist (DPA) aripiprazole (ARP), especially when the switch is abrupt, is likely to fail and sometimes worsen psychosis in schizophrenia patients already under high-dose antipsychotic treatment. Such a switching failure is speculated to be related to be the dopamine supersensitivity state. The risks of switching to the